Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Role of TLR1 and TLR6 in the host defense against disseminated candidiasis.

Netea MG, van de Veerdonk F, Verschueren I, van der Meer JW, Kullberg BJ.

FEMS Immunol Med Microbiol. 2008 Jan;52(1):118-23.

2.

The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis.

Netea MG, Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW, Kullberg BJ.

J Infect Dis. 2002 May 15;185(10):1483-9.

PMID:
11992285
3.

Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells.

Netea MG, Sutmuller R, Hermann C, Van der Graaf CA, Van der Meer JW, van Krieken JH, Hartung T, Adema G, Kullberg BJ.

J Immunol. 2004 Mar 15;172(6):3712-8.

4.

Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice.

Jung YO, Cho ML, Lee SY, Oh HJ, Park JS, Park MK, Park MJ, Ju JH, Kim SI, Park SH, Kim HY, Min JK.

Immunol Lett. 2009 Apr 27;123(2):138-43. doi: 10.1016/j.imlet.2009.03.004.

PMID:
19428561
5.
6.

Fas-FasL interactions modulate host defense against systemic Candida albicans infection.

Netea MG, van Der Meer JW, Meis JF, Kullberg BJ.

J Infect Dis. 1999 Nov;180(5):1648-55.

PMID:
10515828
7.

Pegylated bisacycloxypropylcysteine, a diacylated lipopeptide ligand of TLR6, plays a host-protective role against experimental Leishmania major infection.

Pandey SP, Chandel HS, Srivastava S, Selvaraj S, Jha MK, Shukla D, Ebensen T, Guzman CA, Saha B.

J Immunol. 2014 Oct 1;193(7):3632-43. doi: 10.4049/jimmunol.1400672.

8.

Endogenous interleukin (IL)-1 alpha and IL-1 beta are crucial for host defense against disseminated candidiasis.

Vonk AG, Netea MG, van Krieken JH, Iwakura Y, van der Meer JW, Kullberg BJ.

J Infect Dis. 2006 May 15;193(10):1419-26.

PMID:
16619190
9.

Differential cytokine production and Toll-like receptor signaling pathways by Candida albicans blastoconidia and hyphae.

van der Graaf CA, Netea MG, Verschueren I, van der Meer JW, Kullberg BJ.

Infect Immun. 2005 Nov;73(11):7458-64.

10.

TLR1/TLR2 heterodimers play an important role in the recognition of Borrelia spirochetes.

Oosting M, Ter Hofstede H, Sturm P, Adema GJ, Kullberg BJ, van der Meer JW, Netea MG, Joosten LA.

PLoS One. 2011;6(10):e25998. doi: 10.1371/journal.pone.0025998.

11.
12.
13.

Ureaplasma parvum lipoproteins, including MB antigen, activate NF-{kappa}B through TLR1, TLR2 and TLR6.

Shimizu T, Kida Y, Kuwano K.

Microbiology. 2008 May;154(Pt 5):1318-25. doi: 10.1099/mic.0.2007/016212-0.

PMID:
18451040
14.
15.

Species-specific recognition of Aspergillus fumigatus by Toll-like receptor 1 and Toll-like receptor 6.

Rubino I, Coste A, Le Roy D, Roger T, Jaton K, Boeckh M, Monod M, Latgé JP, Calandra T, Bochud PY.

J Infect Dis. 2012 Mar 15;205(6):944-54. doi: 10.1093/infdis/jir882.

PMID:
22315281
16.
17.

Distinct roles for interleukin-12p40 and tumour necrosis factor in resistance to oral candidiasis defined by gene-targeting.

Farah CS, Hu Y, Riminton S, Ashman RB.

Oral Microbiol Immunol. 2006 Aug;21(4):252-5.

PMID:
16842510
18.

Candida-specific interferon-gamma deficiency and toll-like receptor polymorphisms in patients with chronic mucocutaneous candidiasis.

van der Graaf CA, Netea MG, Drenth IP, te Morsche RH, van der Meer JW, Kullberg BJ.

Neth J Med. 2003 Nov;61(11):365-9.

19.

Toll-like receptor 6 senses Mycobacterium avium and is required for efficient control of mycobacterial infection.

Marinho FA, de Paula RR, Mendes AC, de Almeida LA, Gomes MT, Carvalho NB, Oliveira FS, Caliari MV, Oliveira SC.

Eur J Immunol. 2013 Sep;43(9):2373-85. doi: 10.1002/eji.201243208.

20.

Differential role of IL-18 and IL-12 in the host defense against disseminated Candida albicans infection.

Netea MG, Vonk AG, van den Hoven M, Verschueren I, Joosten LA, van Krieken JH, van den Berg WB, Van der Meer JW, Kullberg BJ.

Eur J Immunol. 2003 Dec;33(12):3409-17.

Supplemental Content

Support Center